You're browsing as a guest. Sign in to unlock all features.
TEM
Tempus AI, Inc.·Health Information Services·United States
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatom...
1 Total1 External0 In-site
TEMTempus AI, Inc.
2025-11-23🏥 HealthcarePitch
Externalby Na's Substack · Other
Tempus AI (TEM): Comprehensive Investment Analysis, Valuation, and Strategic Outlook
TEM: Precision medicine data flywheel creating AI-powered oncology monopoly. Q3 2025 hit +$1.5M adj EBITDA milestone, 140% NRR proves pharma data stickiness. Ambry acquisition adds germline testing scale. DCF fair value ~$88 vs $70-85 trading range. High SBC dilution risk but fortress $764M cash balance.